相关实验视频
Updated: Jun 23, 2026

07:27
Implantation of Total Artificial Heart in Congenital Heart Disease
Published on: July 18, 2014
24.5K
在门诊治疗中怀疑新的心力衰竭:REVOLUTION HF研究
Lisa Anderson1, Antoni Bayes-Genis2, Johan Bodegård3
1Cardiovascular Clinical Academic Group, Molecular and Clinical Sciences Research Institute, St George's, University of London and St George's University Hospitals NHS Foundation Trust, London, UK.
European heart journal
|February 12, 2025
概括
怀疑心力衰竭 (HF) 和高N终端B型亲尿素 (NT-proBNP) 的患者面临高早期死亡率和住院风险. 及时诊断和治疗对于减少不良结果和医疗保健成本至关重要.
科学领域:
- 心脏病学 心脏病学
- 临床医学 临床医学
- 生物标志物研究 生物标志物研究
背景情况:
- 心力衰竭 (HF) 迹象/症状的门诊患者需要进行 natriuretic 测试.
- 怀疑新的HF识别会影响患者的治疗结果和医疗保健的利用.
研究的目的:
- 通过天然尿素测试检查疑似新发性肺炎患者的死亡率,HF住院费用和医疗费用.
- 为了比较疑似新的HF患者的结果与匹配的对照.
主要方法:
- 在瑞典 (2015-2020年) 进行基于人口的研究 (REVOLUTION HF).
- 包括有HF症状和NT-proBNP>300 ng/L的门诊患者.
- 随访5942名患者1年,将他们与2048名匹配的对照人进行比较.
主要成果:
- 在1年内,29%的疑似HF患者得到了诊断.
- 怀疑HF患者的全因死亡率 (11.7对6.5/100人/年) 和HF住院次数 (12.5对2.2/100人/年) 比对照组高.
- 较高的NT-proBNP水平与事件发生率的增加相关;成本是由HF和慢性脏疾病驱动的.
结论:
- 在疑似高风险肺炎患者中,NT-proBNP升高表明高早期死亡率和发病率.
- 与这些患者相关的医疗保健成本很大.
- 紧急识别,评估和治疗HF是必要的.
相关概念视频
Heart Failure I: Introduction
Heart failure refers to a clinical syndrome caused by structural or functional cardiac disorders that prevent the heart from pumping an adequate amount of blood to meet the body's metabolic needs. This condition often arises from myocardial infarction or ischemia, leading to decreased cardiac output, reduced tissue perfusion, impaired gas exchange, fluid volume imbalance, and decreased functional ability.Heart failure can result from disruptions in the mechanisms that regulate cardiac output...
Heart Failure II: Pathophysiology
Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
Heart Failure III: Clinical Manifestations
Heart failure (HF) manifests primarily as dyspnea, fatigue, and fluid retention, resulting in peripheral and pulmonary edema. Symptoms may vary depending on which ventricle is more affected, left or right.Left-Sided Heart FailureAlso known as left ventricular failure, this condition results from the left ventricle's inability to fill or eject sufficient blood into the systemic circulation. It leads to pulmonary congestion, which occurs when the left ventricle fails to eject blood effectively...
Heart Failure IV: Classification and Diagnostic Evaluation
Heart failure can be classified in various ways, with the most common classifications based on physical activity limitations, disease progression, severity, and treatment strategies.The Functional Classification of Heart Failure divides patients into four categories based on physical activity limitation due to symptom burden.Class I: Patients in this class have cardiac disease but no physical activity limitations. Ordinary activities like walking, climbing stairs, or routine tasks do not cause...
Heart Failure V: Medical Management
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
Heart Failure VI: Adjunct Therapies
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.

